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Background: Cool dialysate is often recommended for prevention of intra-dialytic hypotensive episodes in maintenance
hemodialysis (HD) patients. However, its effect on toxin removal is not studied. It is known that inter-compartmental
resistance is the main barrier for toxin removal. Cool dialysate can potentially increase this resistance by vasoconstriction
and thus impair the toxin removal. The aim of this trial is to compare the toxin removal outcome associated with cool vs.
warm dialysate.
Method/design: This study is based on the hypothesis that dialysate temperature, a potential maneuver to maintain
hemodynamic stability during HD, may influence inter-compartmental resistance and hence, toxin removal. Only stable
HD patients will be recruited for this study. The quantum of removed toxins will be assessed by the total spent dialysate,
which is a gold standard to quantify the efficacy of a single dialysis session. Collected samples will be analyzed for urea,
creatinine, phosphate, β2-microglobulin, and uric acid. The study is a single center, self-controlled, randomized prospective
clinical research where 20 study subjects will undergo 2 dialysis sessions: (a) cool dialysis with dialysate at 35.5°C, and
(b) warm dialysis with dialysate at 37°C. Pre- and post-dialysis blood samples will be collected to quantify the dialysis
adequacy and toxin reduction ratio.
Discussion: This is the first clinical research to investigate the effect of dialysate temperature on removal of both
small and large-sized toxins. Successful completion of this research will provide important knowledge pertaining
to dialysate temperature prescription. Results can also lead to the hypothesis that cool dialysate may help in
by preventing intra-dialytic hypotensive episodes, but prolonged prescription of cool dialysate may lead to
comorbidities associated with excess toxin accumulation. The new knowledge will encourage for personalized
dialysate temperature profiling.
Trial registration: Clinicaltrials.gov Identifier - NCT02064153.
Keywords: Hemodialysis, Dialysate temperature, Cool/Warm dialysate, Inter-compartmental resistance, Spent
dialysate, Toxin removalBackground
Improving toxin removal can potentially improve the
hemodialysis (HD) patient outcome. In this context, the
decades old HD procedure progressed from low efficiency
low-flux dialysis to high efficiency high-flux dialysis and
currently towards increased acceptance for convection
based hemodiafiltration (HDF). However, in all these
extracorporeal renal replacement therapies, toxin removal
is primarily impaired by inter-compartmental resistance
[1,2]. Overcoming this resistance seems to be the single* Correspondence: titus_lau@nuhs.edu.sg
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Intra-dialytic exercise may reduce this resistance by
vasodilation. Exercise increases the cardiac output and
reduces peripheral vascular resistance as the vasculature
dilates. This vasodilation may be augmented by in-
creased body core temperature due to exercise [3].
However, intra-dialytic exercise is still considered an
intervention in routine dialysis setting, not a norm.
Also, HD patients with significant muscle wasting may
not be able to exercise during dialysis. How then can we
induce the vasodilation without exercise or can we in-
crease the body core temperature without exercise?ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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change the blood temperature, a surrogate of body core
temperature. Warm dialysate can increase the body core
temperature, resulting in vasodilation and increased
mobilization of sequestered toxins to intravascular com-
partment. The contrary physiological change i.e. vaso-
constriction can similarly be induced by cool dialysate
and this is often recommended for prevention of intra-
dialytic hypotensive (IDH) episodes. IDH is defined as a
fall in systolic blood pressure below 90 mmHg or a drop
of more than 20 mmHg that results in clinical symp-
toms, and occurs in 20-30% of treatments [4-6]. Cool di-
alysate induced vasoconstriction may reduce the toxin
mobilization from remote inaccessible body compart-
ments to intravascular compartment, thus hindering the
toxin removal, which is contrary to the fundamental ob-
jective of HD. Hence, although cool dialysate helps in
prevention of intra-dialytic episodes in short-term, pro-
longed usage may lead to poor patient outcome by im-
paired toxin removal. If cool dialysate does hinder toxin
removal, then for at least 70-80% non-hypotensive HD
patients, the benefits of warm dialysate may be realized.
Few studies have investigated the effect of cool dialysate
on urea removal, and found that urea based dialysis ad-
equacy is largely unaffected by dialysate temperature [7,8].
Nevertheless, it is suggested that urea based adequacy
marker is not a true representative of toxins removal
[9,10], as urea is too small in size and experiences negli-
gible inter-compartmental resistance. Urea kinetics can
also be explained by perfusion term or by regional blood
flow alone [11,12], i.e. change in inter-compartmental re-
sistance will have little effect on its mobilization. The same
does not apply for large-sized toxins [13]. Even other
small-sized toxins do not conform to the kinetic behavior
shown by urea [14,15]. Interestingly, a clinical trial per-
taining to removal of both small and large sized toxins via
dialysate temperature manipulation has never been per-
formed until now. Hence, the aim of this clinical study is
to compare the toxin removal outcome for cool vs. warm
dialysate for both small and large-sized toxins.
Methods and design
Study design and settings
The study is a single center, self-controlled, randomized
study involving patients undergoing conventional high-
flux dialysis. Patients are not informed about the dialysate
temperature a priori; however, some subjects may report
the warm or cool sensation based on their experience. The
study will be conducted at satellite dialysis center of the
National University Hospital (NUH), Singapore.
Ethics approval and quality assurance
The domain specific review board affiliated with the
National Healthcare Group (NHG), Singapore has approvedthe trial. The study will undergo routine quality assurance
review conducted by the ethics board. The ethics board
will also receive timely progress status report from the
principal investigator and will be promptly informed of
any adverse events owing to the study intervention. The
grantor will also receive timely report of study progress.
Patient recruitment
The warm dialysate may result in IDH episodes; hence,
only stable HD subjects with no prior history of IDH
will be recruited for the proposed study. The dialysis
nurses will provide the list of all stable patients in the
past one month. The principal investigator will review
the database of these stable patients. The patients with
history of angina, heart-attack, or chronic obstructive
pulmonary diseases (COPD) will not be recruited for the
trial. Though stable on HD, these patients may be un-
stable during warm dialysis session. The residual renal
function of study subjects should be negligible (defined
by urine output of less than 200 mL/day). Only those
subjects, who follow 3 times per week dialysis schedule,
will be recruited. Subjects satisfying our mentioned criteria
will be contacted. The study administrator will explain
about the intervention and the potential benefits as well as
harms. Agreed subjects will sign the patient information
sheet and consent form. A copy of the consent form
will be provided to the subject. Total 20 subjects will be
recruited for the study.
Inclusion criteria
1. Adult patients male or female (Age > 21 years,
Age < 70 years)
2. Minimum dialysis vintage of 3 months
3. Stable on hemodialysis
4. Blood access capable of delivering the blood flow
rate greater than 250 mL/min
Exclusion criteria
1. History of recurring or persistent hypotension in the
past 1 month
2. Pregnant woman
3. Severely hypertensive patients (SBP > 180 mmHg
and/or DBP > 115 mmHg)
4. Severely hypotensive patients (SBP < 100 mm Hg
and/or DBP < 60 mmHg)
5. Paradoxically hypertensive patients whose BP
increases by more than 20% of baseline during
dialysis (in the past 1 month)
6. History of recent myocardial infarction or unstable
angina (within the past 6 months)
7. Significant valvular disease, i.e. severe aortic stenosis
and moderate-severe mitral regurgitation
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recent or debilitating CVA
9. Patients with Left Ventricular dysfunction, Chronic
Heart Failure and older age group more than 70 years
10. Patient with recent stroke (within the past
6 months)
11. History of known arrhythmia
12. Participation in another clinical intervention trial
13. Unable to consent
Dialysis hypotension may occur in one of three clinical
patterns: (i) acute (episodic) hypotension defined as a sud-
den drop of systolic blood pressure below 90 mmHg or of
at least 20 mmHg with accompanying clinical symptoms,
(ii) recurrent – as detailed above but prevailing in a mini-
mum 50% of dialysis sessions, and (iii) chronic, persistent
hypotension in which interdialytic systolic blood pressure
is maintained at less than 90–100 mmHg.
Study interventions and randomization
All recruited subjects will undergo two study sessions:
(i) cool dialysis with dialysate temperature at 35.5°C and
(ii) warm dialysis with dialysate temperature at 37°C.
The dialysis duration for all sessions will be 240 min. In
total, 40 study sessions will be conducted. The maximum
and minimum interval between two sessions respectively
is one month and one week. Minimum of one week gap is
maintained to avoid any carry over effect from the previ-
ous study session. All dialysis sessions will be performed
using high flux (single-use) dialyzer and the Fresenius
4008S machine. Except dialysate temperature, the dialysis
prescription and patient medications (phosphate binder,
medicine for hypertension, erythropoietin, etc.) will re-
main unchanged. Patients will also be advised to keep
their dietary intake fairly constant during the study period.
Patients are generally fluid overloaded on the beginning
of the week i.e. Monday/Tuesday and target ultrafiltration
(UF) will generally be set higher on those days. This
higher fluid removal requirement may sometimes result
in cramps or hypotensive episodes. Warm dialysate may
aggravate this situation by vasodilation; hence, no study
session will be performed on Monday/Tuesday. The
study sessions for a particular patient will be performed
on the same day of the week. All the study sessions will
be conducted in randomized order, but patient’s existing
dialysis schedule will not be disturbed for the purpose
of the study.
Data collection
Blood and dialysate sampling
During each study session, pre- and post-dialysis blood
samples will be collected. These samples will be analyzed
for both small and large-sized uremic toxins, namely,
urea, creatinine, phosphate, β2-microglobulin, and uricacid. The dialysate flow will be kept at 500 mL/min. Total
spent dialysate will be collected in a large container. To
assess the quantum of removed toxin mass in a particular
study session, the spent dialysate will be analyzed for
the mentioned toxins. The spent dialysate collection is
the gold standard to ascertain session adequacy. All the
samples will be sent to NUH Laboratory Medicine Depart-
ment for analysis. The pre- and post-dialysis blood sam-
ples will be used for calculating the toxin reduction ratio
and urea based dialysis adequacy.
Treatment modification
Study sessions will be discontinued, should adverse-
effects such as acute hypotensive episode (defined by
sudden change in blood pressure – drop of 20 mm Hg
or SBP < 100) or chest pain, uneasiness, or cramps mani-
fest. Although these are anticipated to be at low event
occurrence rate, the event will be medically recorded
and dealt with usual clinical practice. During the session,
if a patient complains about temperature being too high
or too low, then the dialysate temperature will be ad-
justed to his/her routine prescription and subject will be
removed from the study. A report of all such adverse
events will be provided to the ethics board.
Outcome measure
Primary outcome measure
The objective of this clinical study is to investigate the
effect of dialysate temperature on removal of both small
and large-sized toxins. To quantify the removed toxin
mass in an individual study session, the spent dialysate
sample will be analyzed for toxin concentration. The re-
moved toxin mass will potentially depend on the pre-
dialysis toxin concentration. If pre-dialysis toxin concen-
tration is high then there is a possibility that more toxin
mass will be removed; hence removed toxin mass
assessed by spent dialysate will be scaled with respect to
pre-dialysis serum toxin concentration. This scaled re-
moved toxin mass for both study sessions will be com-
pared using standard statistical t-test. The toxin reduction
ratio will also be calculated using pre- and post-dialysis
toxin concentrations.
Secondary outcome measure
Dialysate temperature can potentially change the hemo-
dynamic response. For each study session, patient blood
pressure (BP) and heart rate (HR) will be recorded at
every 5 minutes during the whole study session. If any
sudden change in BP or HR is noticed, the dialysis
nurses will be informed and appropriate clinical action
will be taken. If hemodynamic response is indicative of
hypotensive episode, then study session will be sus-
pended. The schematic flow chart of the study is pre-
sented in Figure 1.
Figure 1 Schematic flow diagram of the clinical study.
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Cool dialysate is often recommended as a potential man-
euver for controlling and/or preventing the incidence of
intra-dialytic hypotensive (IDH) episodes. Cool dialysate
reduces the body core temperature which leads to vaso-
constriction and consequently helps in maintaining
hemodynamic stability during dialysis treatment [5]. It is
suggested that IDH occurs when cardiovascular response
cannot compensate for large volume losses due to exces-
sive UF rate. This can occur under the circumstances
when UF rate exceeds the plasma refilling rate and per-
sists for long enough such that reduction in blood vol-
ume reaches the critical threshold. Importantly, this
critical threshold differs for an individual patient and is
influenced by individual cardiovascular response [16].
This emphasizes the need of individualized dialysate
temperature for prevention of IDH incidence. Before
one aim for individualized dialysate temperature profile,
it is important to study the effect of vasoconstriction on
toxin removal.It has been mentioned that blood cooling has adverse
effect on solute disequilibrium [12]. In a study of un-
stable HD patients, cool dialysate (35°C) was associated
with significantly greater increase in peripheral vascular
resistance [17]. This increased vasoconstriction can po-
tentially reduce the mobilization of toxins from remote
compartments to intravascular compartment, thus redu-
cing the dialysis efficacy. Cool dialysate may be good for
4 hour dialysis, but, in the long term, it may culminate
into various complications due to less efficient removal
of uremic toxins. One such co-morbidity is amyloidosis
due to prolonged accumulation of middle molecule
marker, β2-microglobulin. It will not be wrong to say
that cool dialysate focuses only on one aspect of the dia-
lysis treatment i.e. prevention of IDH, but it must be
weighed against the plausible unwanted negative influ-
ence of impairing an equally important aspect of treat-
ment i.e. uremic toxin removal. Effect of cool dialysate
on urea clearance has been studied, and its removal was
not significantly affected by cool dialysate [4,7,18,19]. It
is because urea is too small in size to experience signifi-
cant inter-compartmental resistance from cellular mem-
brane and/or capillary endothelium. Also, the rapid
equilibration of urea across the cell membrane is essen-
tially due to facilitated transport by selective urea trans-
porters [20]; such transporters do not exist for other
similar sized toxins. Hence, it is imperative to study the
effect of dialysate temperature on toxin removal other
than urea. Interestingly, there is no clinical study which
has investigated the effect of dialysate temperature on
toxin removal. The proposed clinical trial intends to fill
the gap by comparing the toxin removal outcome for cool
and warm dialysate. Contrary to cool dialysate induced
vasoconstriction, warm dialysate will result in vasodilation
and open capillary surface. This will contribute towards
enhanced toxin mobilization from remote inaccessible
compartments to intravascular compartment and their
subsequent removal in the dialyzer. One should also note
that warm dialysate may result in incidence of IDH,
and so only stable on HD subjects will be recruited
for the trial.
Selection of marker toxin is an important aspect in asses-
sing dialysis efficiency. As mentioned earlier, since urea
clearance is unaffected by vasoconstriction or by cool di-
alysate, a better marker should be chosen. In this trial, we
are considering both small and large sized uremic toxins,
namely, urea, creatinine, phosphate, β2-microlgobulin, and
uric acid. Last but not least, the method to assess dialysis
efficiency is important to compare the two study sessions.
Number of criterion like toxin reduction ratio, dialysis
adequacy based on Kt/Vurea, and post-dialytic rebound can
be used. The gold standard is to collect the whole dialysate
or fraction of it continuously [21], analyze a sample from
whole spent dialysate and quantify the removed toxin
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large drums.
Successful completion of this project will encourage
clinicians to refrain from one-size-fit-all approach of
dialysate temperature. Selby and McIntyre have also
recommended the prospect of individualized dialysate
temperature [22]. Further research may lead to patient-
specific dialysate temperature profiling, which will not
only prevent the incidence of intra-dialytic hypotensive
episodes but adjusted to also maximize the toxin removal.
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